{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:30:02Z","timestamp":1787239802035,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","issue":"31","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T00:00:00Z","timestamp":1686355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["19pc0101043h0001"],"award-info":[{"award-number":["19pc0101043h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["22fk0108141j0003"],"award-info":[{"award-number":["22fk0108141j0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.vaccine.2023.06.019","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T12:50:54Z","timestamp":1686833454000},"page":"4525-4533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Post-fusion influenza vaccine adjuvanted with SA-2 confers heterologous protection via Th1-polarized, non-neutralizing antibody responses"],"prefix":"10.1016","volume":"41","author":[{"given":"Ayae","family":"Nishiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Tonouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2057-9198","authenticated-orcid":false,"given":"Saya","family":"Moriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1691-2210","authenticated-orcid":false,"given":"Masamitsu","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Asanuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Shirakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihisa","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3753-1211","authenticated-orcid":false,"given":"Takuya","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.06.019_b0005","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1128\/JVI.02749-12","article-title":"Reassortment complements spontaneous mutation in influenza A virus NP and M1 genes to accelerate adaptation to a new host","volume":"87","author":"Ince","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.06.019_b0010","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/infdis\/jiv579","article-title":"Influenza vaccine effectiveness: mysteries, enigmas, and a few clues","volume":"213","author":"Pavia","year":"2016","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2023.06.019_b0015","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/infdis\/jiy103","article-title":"A universal influenza vaccine: the strategic plan for the national institute of allergy and infectious diseases","volume":"218","author":"Erbelding","year":"2018","journal-title":"J Infect Dis"},{"issue":"85","key":"10.1016\/j.vaccine.2023.06.019_b0020","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002336","article-title":"MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines","volume":"3","author":"Khurana","year":"2011","journal-title":"Sci Transl Med"},{"issue":"31","key":"10.1016\/j.vaccine.2023.06.019_b0025","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1016\/j.vaccine.2012.04.089","article-title":"Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial","volume":"30","author":"Pleguezuelos","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2023.06.019_b0030","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41591-020-1118-7","article-title":"A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial","volume":"27","author":"Nachbagauer","year":"2021","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.vaccine.2023.06.019_b0035","doi-asserted-by":"crossref","DOI":"10.3390\/v13071280","article-title":"Universal live-attenuated influenza vaccine candidates expressing multiple M2e epitopes protect ferrets against a high-dose heterologous virus challenge","volume":"13","author":"Mezhenskaya","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2023.06.019_b0040","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2016.05.073","article-title":"Structure and function analysis of an antibody recognizing all influenza a subtypes","volume":"166","author":"Kallewaard","year":"2016","journal-title":"Cell"},{"issue":"6044","key":"10.1016\/j.vaccine.2023.06.019_b0045","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1205669","article-title":"A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins","volume":"333","author":"Corti","year":"2011","journal-title":"Science"},{"issue":"6100","key":"10.1016\/j.vaccine.2023.06.019_b0050","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.1222908","article-title":"Highly conserved protective epitopes on influenza B viruses","volume":"337","author":"Dreyfus","year":"2012","journal-title":"Science"},{"issue":"21","key":"10.1016\/j.vaccine.2023.06.019_b0055","doi-asserted-by":"crossref","first-page":"11048","DOI":"10.1128\/JVI.05397-11","article-title":"Naturally occurring antibodies in humans can neutralize a variety of influenza virus strains, including H3, H1, H2, and H5","volume":"85","author":"Ohshima","year":"2011","journal-title":"J Virol"},{"issue":"7417","key":"10.1016\/j.vaccine.2023.06.019_b0060","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nature11414","article-title":"Cross-neutralization of influenza A viruses mediated by a single antibody loop","volume":"489","author":"Ekiert","year":"2012","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.vaccine.2023.06.019_b0065","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.cell.2019.03.048","article-title":"Antibodies to a conserved influenza head interface epitope protect by an IgG subtype- dependent mechanism","volume":"177","author":"Watanabe","year":"2019","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.vaccine.2023.06.019_b0070","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.cell.2019.04.011","article-title":"A site of vulnerability on the influenza virus hemagglutinin head domain trimer interface","volume":"177","author":"Bangaru","year":"2019","journal-title":"Cell"},{"issue":"44","key":"10.1016\/j.vaccine.2023.06.019_b0075","doi-asserted-by":"crossref","first-page":"18979","DOI":"10.1073\/pnas.1013387107","article-title":"Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes","volume":"107","author":"Wang","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.vaccine.2023.06.019_b0080","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-11821-6","article-title":"Exposure of an occluded hemagglutinin epitope drives selection of a class of cross-protective influenza antibodies","volume":"10","author":"Adachi","year":"2019","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.vaccine.2023.06.019_b0085","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1084\/jem.20142284","article-title":"Distinct germinal center selection at local sites shapes memory B cell response to viral escape","volume":"212","author":"Adachi","year":"2015","journal-title":"J Exp Med"},{"issue":"9","key":"10.1016\/j.vaccine.2023.06.019_b0090","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/intimm\/dxaa038","article-title":"Stereotyped B-cell response that counteracts antigenic variation of influenza viruses","volume":"32","author":"Tonouchi","year":"2020","journal-title":"Int Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2023.06.019_b0095","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm.3443","article-title":"Broadly neutralizing hemagglutinin stalk-specific antibodies require Fc\u03b3R interactions for protection against influenza virus in vivo","volume":"20","author":"DiLillo","year":"2014","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.vaccine.2023.06.019_b0100","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.chom.2016.05.014","article-title":"Both neutralizing and non-neutralizing human H7N9 influenza vaccine-induced monoclonal antibodies confer protection","volume":"19","author":"Henry Dunand","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2023.06.019_b0105","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3389\/fimmu.2013.00076","article-title":"Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies","volume":"4","author":"Seidel","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2023.06.019_b0110","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4049\/jimmunol.1400432","article-title":"Influenza-specific antibody-dependent cellular cytotoxicity: toward a universal influenza vaccine","volume":"193","author":"Jegaskanda","year":"2014","journal-title":"J Immunol"},{"issue":"25","key":"10.1016\/j.vaccine.2023.06.019_b0115","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000759","article-title":"Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes","volume":"2","author":"Koyama","year":"2010","journal-title":"Sci Transl Med"},{"issue":"8","key":"10.1016\/j.vaccine.2023.06.019_b0120","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1073\/pnas.1319268111","article-title":"Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist","volume":"111","author":"Kobiyama","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.vaccine.2023.06.019_b0125","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/eji.201546059","article-title":"Species-dependent role of type I IFNs and IL-12 in the CTL response induced by humanized CpG complexed with \u03b2-glucan","volume":"46","author":"Kobiyama","year":"2016","journal-title":"Eur J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2023.06.019_b0130","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/intimm\/dxy069","article-title":"A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer Fc\u03b3R-mediated protection against heterologous lethal influenza virus infection","volume":"31","author":"Yamamoto","year":"2019","journal-title":"Int Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2023.06.019_b0135","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.4049\/jimmunol.1600046","article-title":"Whole-virion influenza vaccine recalls an early burst of high-affinity memory B cell response through TLR signaling","volume":"196","author":"Onodera","year":"2016","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2023.06.019_b0140","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.4049\/jimmunol.1601129","article-title":"A new RNA-based adjuvant enhances virus-specific vaccine responses by locally triggering TLR- and RLH-dependent effects","volume":"198","author":"Ziegler","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2023.06.019_b0145","doi-asserted-by":"crossref","DOI":"10.1038\/srep19570","article-title":"Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens","volume":"6","author":"Knudsen","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2023.06.019_b0150","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-01372-5","article-title":"A humanized mouse model identifies key amino acids for low immunogenicity of H7N9 vaccines","volume":"7","author":"Wada","year":"2017","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.vaccine.2023.06.019_b0155","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.4161\/hv.25458","article-title":"Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults","volume":"9","author":"Ainai","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.vaccine.2023.06.019_b0160","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/jmv.22273","article-title":"Characterization of neutralizing antibodies in adults after intranasal vaccination with an inactivated influenza vaccine","volume":"84","author":"Ainai","year":"2012","journal-title":"J Med Virol"},{"issue":"33","key":"10.1016\/j.vaccine.2023.06.019_b0165","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1016\/j.vaccine.2011.05.061","article-title":"Vaccine adjuvant activity of 3M\u2013052: an imidazoquinoline designed for local activity without systemic cytokine induction","volume":"29","author":"Smirnov","year":"2011","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2023.06.019_b0170","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4049\/immunohorizons.1700063","article-title":"Recent advances in the discovery and delivery of TLR7\/8 agonists as vaccine adjuvants","volume":"2","author":"Dowling","year":"2018","journal-title":"Immunohorizons"},{"issue":"2","key":"10.1016\/j.vaccine.2023.06.019_b0175","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.4049\/jimmunol.0902147","article-title":"Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection","volume":"186","author":"El Bakkouri","year":"2011","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2023.06.019_b0180","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1172\/JCI84428","article-title":"Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection","volume":"126","author":"DiLillo","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2023.06.019_b0185","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1016\/j.vaccine.2011.09.061","article-title":"The mechanism of action of MF59 - an innately attractive adjuvant formulation","volume":"30","author":"O\u2019Hagan","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.06.019_b0190","doi-asserted-by":"crossref","unstructured":"Dupuis M, Denis-Mize K, LaBarbara A, Peters W, Charo IF, McDonald DM. et al. Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis Eur J Immunol. 2001; 31(10):2910-8. doi: 10.1002\/1521-4141(2001010)31:10<2910::aid-immu2910>3.0.co;2-3.","DOI":"10.1002\/1521-4141(2001010)31:10<2910::AID-IMMU2910>3.0.CO;2-3"},{"issue":"30","key":"10.1016\/j.vaccine.2023.06.019_b0195","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1073\/pnas.0804699105","article-title":"Molecular and cellular signatures of human vaccine adjuvants","volume":"105","author":"Mosca","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2023.06.019_b0200","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00406","article-title":"Novel lipidated imidazoquinoline TLR7\/8 adjuvants elicit influenza-specific Th1 immune responses and protect against heterologous H3N2 influenza challenge in mice","volume":"11","author":"Miller","year":"2020","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2023.06.019_b0205","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1016\/j.vaccine.2020.01.066","article-title":"Fc functional antibody responses to adjuvanted versus unadjuvanted seasonal influenza vaccination in community-dwelling older adults","volume":"38","author":"Vanderven","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.06.019_b0210","doi-asserted-by":"crossref","unstructured":"Levine MZ, Holiday C, Bai Y, Zhong W, Liu F, Jefferson S. et al. Influenza A(H7N9) Pandemic Preparedness: Assessment of the Breadth of Heterologous Antibody Responses to Emerging Viruses from Multiple Pre-Pandemic Vaccines and Population Immunity, Vaccines (Basel). 2022; 10(11):1856. doi: 10.3390\/vaccines10111856.","DOI":"10.3390\/vaccines10111856"},{"issue":"8","key":"10.1016\/j.vaccine.2023.06.019_b0215","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/infdis\/jiz295","article-title":"Stockpiled avian influenza A(H7N9) vaccines induce robust, nonneutralizing functional antibodies against antigenically drifted fifth-wave A(H7N9) viruses","volume":"220","author":"Zhong","year":"2019","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2023.06.019_b0220","doi-asserted-by":"crossref","first-page":"e01596","DOI":"10.1128\/JVI.01596-16","article-title":"Superiority in rhesus macaques of targeting HIV-1 env gp140 to CD40 versus LOX-1 in combination with replication-competent NYVAC-KC for induction of env-specific antibody and T cell responses","volume":"91","author":"Zurawski","year":"2017","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2023.06.019_b0225","doi-asserted-by":"crossref","first-page":"e01529","DOI":"10.1128\/JVI.01529-18","article-title":"Priming with a potent HIV-1 DNA vaccine frames the quality of immune responses prior to a poxvirus and protein boost","volume":"93","author":"Asbach","year":"2019","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23006850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23006850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:29:12Z","timestamp":1759404552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23006850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":45,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0264410X23006850"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.06.019","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-fusion influenza vaccine adjuvanted with SA-2 confers heterologous protection via Th1-polarized, non-neutralizing antibody responses","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}